Feasibility and Safety of Anlotinib Combined with Immune Checkpoint Inhibitors in Patients with Previously Immunotherapy-Treated Extensive-Stage Small Cell Lung Cancer: A Retrospective Exploratory Study.

Drug Des Devel Ther · 2025 · PMC12164881 · PMID 40521010

Europe PMC DOI

hedged sentence

0.1360

closest p · 2.7× alpha

0.1360

boldest claim

The sentences

showed a trendP = 0.136not close (p > 0.1)

Interestingly, the median PFS of patients receiving 8 mg, 10 mg and 12 mg anlotinib was 3.0 months (95% CI: 1.54–4.46), 6.1 months (95% CI: 3.71–8.49) and 7.8 months (95% CI: 0.00–17.91), respectively, which showed a trend toward statistical significance ( P = 0.136).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.